Looking into the "Garden of the Hesperides": new drugs for hepatocellular carcinoma

Advanced hepatocellular carcinoma remains an entity that is hard to approach therapeutically and has shown disappointing results in terms of survival. For many years, the only accepted option for this setting was the use of a multikinase inhibitor, sorafenib. Nevertheless, through the years, a deeper knowledge has arisen about how pathogenic pathways correlate with hepatocellular carcinoma. In this review, we provide an update of the most recent data regarding new agents under investigation and new possible targets for future treatments..

Medienart:

Artikel

Erscheinungsjahr:

2015

Erschienen:

2015

Enthalten in:

Zur Gesamtaufnahme - volume:70

Enthalten in:

Minerva chirurgica - 70(2015), 2, Seite 119

Sprache:

Englisch

Beteiligte Personen:

Castañón Alvarez, E [VerfasserIn]
Giallombardo, M [Sonstige Person]
Gil-Bazo, I [Sonstige Person]
Papadimitriou, K [Sonstige Person]
Pauwels, P [Sonstige Person]
Peeters, M [Sonstige Person]
Rolfo, C [Sonstige Person]

Links:

www.ncbi.nlm.nih.gov

Themen:

Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - therapy
Immunotherapy - methods
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - therapy
Multiprotein Complexes - pharmacology
Multiprotein Complexes - therapeutic use
Proto-Oncogene Proteins c-met - antagonists & inhibitors
TOR Serine-Threonine Kinases - pharmacology
TOR Serine-Threonine Kinases - therapeutic use
Wnt Signaling Pathway - drug effects

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC1956376755